سعر روتاجريست 12.5مجم/50مل محلول وريدي 50 مل 2022

Tirofiban 12.5 mg/50 ml (250 mcg/ml) concentrate for intravenous infusion, 50 ml; manufactured by Alexandria (company) for Rotabiogen.

• Prevention of early myocardial infarction in adults with NSTE-ACS (last chest pain within 12 h, with ECG changes and/or elevated cardiac enzymes).Population: Adultselectronic medicines compendium (emc)
• Reduction of major cardiovascular events in acute STEMI intended for primary PCI.Population: Adultselectronic medicines compendium (emc)
• Reduce the rate of thrombotic cardiovascular events in NSTE-ACS.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Bleeding is most common (mostly mild mucocutaneous or catheter-site); GI, retroperitoneal, intracranial and other serious bleeding reported; thrombocytopenia (<90,000/mm3) in 1.5% with heparin.International label, same formulation · electronic medicines compendium (emc)

• Hypersensitivity; thrombocytopenia with prior GP IIb/IIIa antagonist; stroke within 30 days or any haemorrhagic stroke; intracranial disease; active/recent bleeding; malignant hypertension; major trauma/surgery within 6 weeks; platelets <100,000/mm3; clotting disturbances (INR >1.5); severe liver failure.International label, same formulation · electronic medicines compendium (emc)
• US label: severe hypersensitivity; history of thrombocytopenia after prior Aggrastat; active internal bleeding, bleeding diathesis, major surgery or severe trauma within the previous month.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Not recommended without unfractionated heparin or with thrombolytics; monitor carefully for bleeding (higher in elderly, women, low body weight, CrCl <60 ml/min, femoral access); stop immediately for major bleeding, emergency CABG or IABP.International label, same formulation · electronic medicines compendium (emc)

• Thrombolytics; drugs increasing bleeding risk (e.g. clopidogrel, ticlopidine, dipyridamole, enoxaparin)Combination with thrombolytics not recommended; special caution with other antiplatelets/anticoagulants due to increased bleeding risk.electronic medicines compendium (emc)

• No or limited data in pregnant women; not recommended during pregnancy unless clearly necessary (UK SmPC).International label, same formulation · electronic medicines compendium (emc)
• US label: published case reports have not established an association with major birth defects, miscarriage or adverse outcomes; untreated MI can be fatal to mother and fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Unknown whether excreted in human milk (excreted in animal milk); decide whether to discontinue breastfeeding or therapy.International label, same formulation · electronic medicines compendium (emc)

• Tirofiban: Reversible non-peptide antagonist of fibrinogen binding to the platelet GP IIb/IIIa receptor, inhibiting platelet aggregation.